|
Patent landscape, scope, and claims summary: |
Executive summary
United States Patent 5,091,318 claims an IgE detection device, method, and kit built around allergen immobilized on a solid phase (notably nitrocellulose), where the allergen is first pretreated/conditioned with specific “pretreatment substances” (denaturants excluding organic solvents; organic solvents; crosslinkers; concentrated salt solutions; including enumerated examples such as HCl, acetic acid, THF, NaCl, formaldehyde, glutaraldehyde, and EDC), optionally with a protein blocking reagent. Claim scope is driven by (i) the material of the solid support and (ii) the chemistry of allergen pretreatment (including specific reagent lists and ranges).
Critical implication: the core inventive contribution is not “immunoassay-on-a-membrane” generally, but immunoassays using a specific allergen immobilization scheme tied to the pretreatment system and support selection. In a freedom-to-operate (FTO) sense, the strongest risk is for platforms that (a) use nitrocellulose (or derivatives) as the capture phase and (b) immobilize allergens using one of the claimed pretreatment regimes (especially crosslinking or denaturation/salt/solvent pretreatments, and particularly enumerated agents and defined volume/concentration embodiments).
Because the user-provided prompt contains only the claim text and not filing/publication data, cited references, prosecution history, or the full patent family, a complete, citation-grade landscape across US and major foreign jurisdictions cannot be produced from the available information.
What patents are likely to be affected by 5,091,318’s claim structure?
A quick claim-to-asset map
- Capture phase constraint: “solid phase” selected from nitrocellulose / nitrocellulose derivatives / nitrocellulose compounds (device) and broader solid-phase lists in dependent claims (cellulose/cellulose derivatives, silica, fiberglass, porous polymer matrices/gels/films, agarose, porous fibrous matrices).
- Allergen immobilization constraint: allergen applied as an “allergen composition” formed by combining the allergen with a pretreatment substance selected from a closed list plus enumerated exemplars.
- Pretreatment chemistry constraint (central):
- Denaturants excluding organic solvents and concentrated salt solutions
- Organic solvents
- Crosslinking agents
- Concentrated salt solutions
- Examples explicitly claimed:
- Hydrochloric acid / acetic acid
- Tetrahydrofuran (THF)
- Concentrated sodium chloride
- Formaldehyde / glutaraldehyde / EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide)
- Optional improvements: protein blocking reagent (equine serum albumin, bovine serum albumin, fish gelatin, casein).
- Allergen load examples: large enumerated list of allergens (Alternaria, Aspergillus, Bermuda grass, birch, cat, cedar, grasses, ragweed, dust, etc.) with broad protein concentration ranges. These ranges can function as additional claim hooks for formulation-level avoidance.
- Assay format: immobilized allergen-specific IgE captured from sample; detection via indicator reagent (labeled binding member specific for allergen/IgE/ancillary binding member; anti-IgE label; label types include fluorescent/chemiluminescent/radioisotope/enzymatic/latex/liposomes, etc.).
How does 5,091,318 define claim scope and where are the tightest boundaries?
-
Independent device claim (Claim 1) is tightest on:
- Nitrocellulose(-based) solid phase
- Allergen applied as an allergen composition (not simply “allergen immobilized”)
- Pretreatment substances limited to the claimed categories.
-
Dependent claims broaden support materials but still keep the pretreatment system as the binding constraint (device claim 6, 7; method claim 16, 17).
-
The “allergen composition” claims (19–41) separate the pretreatment step as an independent object:
- Claim 19 focuses on solvent + allergen solubilized + pretreatment to form an allergen composition “used for in vitro detection” of IgE.
- Many subsequent dependent claims narrow pretreatment to specific reagents and even volume/amount ranges (formaldehyde microliter volumes; THF microliter volumes; NaCl molarity; EDC + sodium borohydride amounts; acetic acid buffered to pH 7; HCl buffered to pH 7).
Which claim elements are most likely to drive infringement vs. non-infringement design-arounds?
-
High infringement leverage elements (harder to design around):
- Use of nitrocellulose as the solid support (at least for device claim 1).
- Use of one of the claimed pretreatment regimes for allergen immobilization (especially those explicitly named).
- Using an indicator reagent with labeled anti-IgE for detection (method claims 44–46).
-
High design-around leverage elements (easier to change, depending on technical constraints):
- Replacing nitrocellulose with a non-claimed support (though note many dependent claims still cover other supports; and independent method/kit claims still retain nitrocellulose in several places).
- Avoiding use of the enumerated pretreatment agents and falling outside the pretreatment categories (though “denaturants excluding organic solvents and concentrated salt solutions” and broad “organic solvents/crosslinking agents/concentrated salts” may still capture many common immobilization schemes).
- Altering pretreatment timing/chemistry such that the allergen is not “applied as an allergen composition formed from the combination of allergen with a pretreatment substance” as claimed.
Which other patents commonly overlap with 5,091,318’s allergen-IgE membrane immobilization concept?
Adjacent IP likely to cluster in the same technical space
Given claim content, overlapping patent estates typically fall into these buckets:
- Allergen immobilization on membranes/supports for IgE immunoassays
- nitrocellulose-based immunobinding matrices
- formaldehyde or carbodiimide-mediated coupling systems
- denaturation-assisted adsorption onto membranes
- Pretreatment chemistry for preserving allergen antigenicity during immobilization
- pH-conditioned solubilization/conditioning before immobilization
- solvent or chaotrope-based conditioning
- Lateral flow or solid-phase IgE detection kits
- labeled anti-IgE conjugates
- washing and blocking systems
- General immunoassay formats
- contacting sample, forming antigen-antibody complexes, detecting via labeled binding members
- indicator labels including enzymes, fluorophores, chemiluminescence, particles, liposomes
Critical point for landscape analysis
In enforcement or licensing, a litigant typically argues 5,091,318’s differentiator is the combination of:
- support selection (nitrocellulose) +
- specific allergen pretreatment categories and exemplars +
- immobilization/drying process +
- assay detection system (anti-IgE labeling).
Competing patents that change only the detection chemistry but keep the pretreatment/support combination may still overlap strongly; conversely, patents that change pretreatment chemistry and use alternative supports can be more meaningfully separated.
What patents protect allergen immobilized on nitrocellulose for IgE assays, and how many claim-preemptive families exist?
A quantitative answer requires bibliographic and citation mining (US patent number mappings, CPC/IPC clustering, citation graph analysis, and family-level boundaries). The prompt provides only one patent’s claim text and no linked datasets, so a defensible count cannot be produced.
When does US Patent 5,091,318 lose exclusivity, and what is the relevant term expiration date?
A timeline requires the patent’s issue date, filing date, and any term adjustment or PTA. The prompt provides only the patent number and claims, not issuance or priority dates. A precise expiration analysis cannot be produced from the available information.
What is the Orange Book status of 5,091,318, and does it tie to any marketed product?
The Orange Book status depends on whether the patent is listed for a drug application (NDA/ANDA/BLA). The patent in the prompt appears to be a diagnostic assay device/kit rather than a therapeutic, and Orange Book typically does not list most diagnostics. Without FDA application identifiers and Orange Book data, a status call cannot be made.
How strong is the patent estate for 5,091,318 (claim breadth vs. likely prior art)?
Breadth indicators inside the claim set
- The independent device claim is constrained to nitrocellulose(-based supports, which can narrow the field).
- The pretreatment step is broad in concept but limited in listed categories and explicit examples; dependent claims narrow further with reagent names and quantified amounts.
- The method and kit claims largely track the device claim and include indicator reagent options (broad label categories), which could increase potential coverage.
Likely prior-art pressure points
Even without searching, the claim reads like it targets a known technical routine: membrane solid phase with immobilized allergen and detection of IgE using labeled anti-IgE. The novelty, per the claims, is the pretreatment regimen and its linkage to allergen immobilization on selected solid supports, including drying and optional blocking.
Litigation posture implications
- If an accused product uses membrane-only immobilization with standard adsorption (no claimed pretreatment), it can argue non-infringement on the pretreatment element.
- If it uses standard chemical crosslinking not within the claimed pretreatment set (or uses different crosslinkers not captured by “crosslinking agents” argument boundaries), the outcome hinges on claim construction.
- If it uses formaldehyde/glutaraldehyde/EDC or acid conditioning/THF/NaCl concentration regimes, the pretreatment match risk is higher.
What generic entry risks exist for IgE allergen test kits covered by 5,091,318?
“Generic entry” for diagnostics typically maps to design-around entry rather than ANDA-style equivalence. Risk is concentrated in:
- suppliers replicating the immobilization chemistry
- kit manufacturers using nitrocellulose strips and the claimed pretreatment system
- competitors adopting the same blocking/drying workflow
A specific launch-risk assessment requires identification of practicing products and their manufacturing chemistry, which cannot be derived from the prompt.
How do 5,091,318’s claims compare with other IgE diagnostic immobilization patents (carbodiimide/crosslinking vs. adsorption)?
Core comparison axis
- 5,091,318: immobilization preceded by pretreatment with denaturants/solvents/salts/crosslinkers, including explicit exemplars and some pH conditions.
- Many other estates either:
- rely on direct adsorption without solvent/acid or defined pretreatments; or
- rely on non-matching coupling chemistries (different functional groups/crosslinkers); or
- use different support chemistries and immobilization sequences.
A real comparison needs a patent corpus; none is available in the prompt.
What patent litigation affects 5,091,318, and are there settlement agreements or PTAB rulings?
Litigation status requires court docket mining (PACER/RECAP) and PTAB decision data. The prompt includes no litigation identifiers, venues, or parties. A litigation analysis cannot be produced.
Key Takeaways
- US 5,091,318 claims IgE immunoassay devices/kits where allergen immobilization is preceded by defined “pretreatment” chemistry and performed on nitrocellulose(-based) solid phases for the core device claim.
- The strongest practical infringement hook is the pretreatment element (acid/solvent/salt/crosslinker families, with explicit examples like HCl/acetic acid, THF, NaCl, formaldehyde/glutaraldehyde/EDC) coupled with the support and the allergen application/drying workflow.
- Dependent claims add significant narrowing detail: blocking reagents, specific allergen concentration ranges, and quantified pretreatment volumes/amounts.
- A defensible “comprehensive and critical analysis” of the broader US and foreign patent landscape, exclusivity timelines, Orange Book status, and litigation posture cannot be completed from the claim text alone.
FAQs
- Can a competitor avoid 5,091,318 by using a different label (e.g., fluorescent vs. enzyme)?
- If an accused device uses nitrocellulose but omits chemical pretreatment, which claim element typically becomes the infringement pinch point?
- Do the allergen protein concentration ranges in 5,091,318 create additional infringement exposure for competitors that use different dosing concentrations?
- How do the quantified pretreatment embodiments (e.g., formaldehyde microliter ranges, THF microliter ranges) change design-around strategy?
- What manufacturing workflow changes (order of mixing, drying conditions, blocking) most directly target claim limitations in 5,091,318?
References (APA)
- United States Patent 5,091,318.
More… ↓
⤷ Start Trial
|
